Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
2.

Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.

Simpson KN, Simpson AN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP; IMS III Investigators.

Stroke. 2014 Jun;45(6):1791-8. doi: 10.1161/STROKEAHA.113.003874. Epub 2014 May 13.

3.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

4.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
5.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
6.

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P.

Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23.

PMID:
21953539
7.

Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.

Zachrisson O, Zhao M, Andersson A, Dannaeus K, Häggblad J, Isacson R, Nielsen E, Patrone C, Rönnholm H, Wikstrom L, Delfani K, McCormack AL, Palmer T, Di Monte DA, Hill MP, Janson Lang AM, Haegerstrand A.

J Parkinsons Dis. 2011;1(1):49-63. doi: 10.3233/JPD-2011-0003.

PMID:
23939256
8.

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E.

PLoS One. 2010 Nov 22;5(11):e14053. doi: 10.1371/journal.pone.0014053.

9.

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51. doi: 10.1017/S1461145710000775. Epub 2010 Jul 22.

PMID:
20663270
10.

Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I.

Exp Neurol. 2009 Oct;219(2):574-82. doi: 10.1016/j.expneurol.2009.07.019. Epub 2009 Jul 25.

PMID:
19635479
11.

Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.

Scheller D, Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M, Bezard E.

Neurosci Lett. 2008 Feb 13;432(1):30-4. Epub 2007 Dec 8.

PMID:
18162314
12.

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.

Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E.

Exp Neurol. 2007 Feb;203(2):415-22. Epub 2006 Oct 12.

PMID:
17045989
13.

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.

Mov Disord. 2006 Dec;21(12):2090-5.

PMID:
16991143
14.

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM.

FASEB J. 2005 Jul;19(9):1140-2. Epub 2005 May 13.

PMID:
15894565
15.

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E.

Trends Pharmacol Sci. 2004 May;25(5):249-53. Review.

PMID:
15120490
16.

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. Epub 2004 Mar 5.

17.

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.

Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

Eur J Pharmacol. 2004 Feb 6;485(1-3):159-64.

PMID:
14757136
18.

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.

Mov Disord. 2003 Nov;18(11):1301-5.

PMID:
14639671
19.

Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease.

Hill MP, Hille CJ, Brotchie JM.

Drug News Perspect. 2000 Jun;13(5):261-8.

PMID:
12937640
20.

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.

Mov Disord. 2003 Aug;18(8):872-83.

PMID:
12889076

Supplemental Content

Loading ...
Support Center